

ANTIGENICS INC /DE/  
Form 3  
June 09, 2008

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â Valentine Karen		(Month/Day/Year)	ANTIGENICS INC /DE/ [agen]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		06/04/2008		
C/O ANTIGENICS INC.,Â 3 FORBES RD			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
LEXINGTON,Â MAÂ 02421			(give title below)	(specify below)
(City)	(State)	(Zip)	VP and General Counsel	
				6. Individual or Joint/Group Filing(Check Applicable Line)
				<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,106	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title			

Edgar Filing: ANTIGENICS INC /DE/ - Form 3

		Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Stock Option, right to buy	03/22/2005 <sup>(1)</sup>	03/22/2014	Common Stock	15,000	\$ 10.17	D	Â
Stock Option, right to buy	03/07/2006 <sup>(2)</sup>	03/07/2015	Common Stock	7,500	\$ 6.3	D	Â
Stock Option, right to buy	01/01/2007 <sup>(3)</sup>	01/01/2016	Common Stock	7,500	\$ 4.76	D	Â
Stock Option, right to buy	03/22/2007 <sup>(4)</sup>	03/22/2016	Common Stock	7,500	\$ 5.13	D	Â
Stock Option, right to buy	09/15/2007 <sup>(5)</sup>	09/15/2016	Common Stock	12,500	\$ 1.63	D	Â
Stock Option, right to buy	12/04/2007 <sup>(6)</sup>	12/04/2016	Common Stock	30,000	\$ 2.03	D	Â
Restricted Stock	01/05/2009 <sup>(7)</sup>	01/05/2017	Common Stock	5,209	\$ 0	D	Â
Stock Option, right to buy	09/12/2008 <sup>(8)</sup>	09/12/2017	Common Stock	48,900	\$ 2.27	D	Â
Restricted Stock	07/10/2008 <sup>(9)</sup>	01/10/2018	Common Stock	16,376	\$ 0	D	Â
Restricted Stock	01/10/2009 <sup>(10)</sup>	01/10/2018	Common Stock	16,375	\$ 0	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Valentine Karen C/O ANTIGENICS INC. 3 FORBES RD LEXINGTON, MA 02421	Â	Â	Â VP and General Counsel	Â

## Signatures

Christine M. Klaskin, by Power of Attorney 06/09/2008

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options vest in four equal annual installments beginning March 22, 2005.
- (2) Options vest in four equal annual installments beginning March 7, 2006.

### Edgar Filing: ANTIGENICS INC /DE/ - Form 3

- (3) Options vest in four equal annual installments beginning January 1, 2007.
- (4) Options vest in three equal annual installments beginning March 22, 2007.
- (5) Options vest 33% on September 15, 2007 and 67% on September 15, 2008.
- (6) Options vest in four equal annual installments beginning December 4, 2007.
- (7) Restricted Stock granted in accordance with the terms of the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests on January 5, 2009.
- (8) Options vest in four equal annual installments beginning September 12, 2008.
- (9) Restricted Stock granted in accordance with the Antigenics Inc. 1999 Equity Incentive Plan, as amended and vests on July 10, 2008.
- (10) Restricted Stock granted in accordance with the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests on January 10, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.